PRCT's Q1 Demand Solid, But Cash Burn Remains the Overhang

What happened

PROCEPT BioRobotics presented at the Bank of America Healthcare Conference, reinforcing Q1'26 metrics: U.S. procedures grew ~30% YoY, installed base hit 765 systems (+40%), and handpiece ASP held at ~$3,500 after incentive removal. However, reported revenue of $83.1M (+20% YoY) lagged procedure growth due to inventory normalization, with handpieces sold at ~95% of procedures. Gross margin stabilized at 65%, but operating expenses rose to $86.6M, driving adjusted EBITDA loss to $(18.1)M and operating cash outflow to $(38.1)M. Management reiterated expectations for a stronger 2H26 as normalization fades, but the market remains skeptical given accelerating cash burn and no near-term profitability path. The stock at $24 (~3x FY26 revenue) prices in a recovery that must be proven by sequential EBITDA and cash flow improvement in Q2-Q3.

Implication

PRCT's thesis hinges on Q2-Q3 proving that inventory normalization ends, handpiece/procedure ratio sustains ~95%+, and adjusted EBITDA loss sequentially improves from $(18.1)M. If those milestones are met, the stock could re-rate toward $28-$36 as revenue quality and margin clarity return. However, if operating cash burn persists above $(35)M per quarter, dilution risk rises and the stock could test $16. The conference message did not alter these near-term scorecards; thus investors should maintain disciplined entry only after clear operating leverage signals.

Thesis delta

The conference presentation provided no new data or guidance shifts; management's narrative remains consistent with the Q1 earnings call. The thesis delta is neutral: the investment case continues to depend on Q2-Q3 execution against the disclosed milestones (handpiece/procedure ratio, ASP, EBITDA improvement). No reason to adjust rating or conviction yet.